How Rep. Delaney Committee Roles Align Perfectly with Her Trades
)
Some lawmakers make headlines for what they say in committee hearings. Others, like Rep. April Delaney, make waves with what they buy.
Back in April 2025, Delaney purchased roughly $120,000 worth of IDEXX Laboratories (IDXX:US), a veterinary diagnostics and biotech firm. The timing wasn’t just good, it was remarkable. That same month, the National Biotechnology Initiative Act of 2025 was introduced in Congress, a bill aimed at boosting U.S. competitiveness in biotech research and development.
The bill was referred to two key committees: Agriculture and Science, Space & Technology. Delaney sits on both.
Whether coincidence or foresight, the move paid off handsomely. IDXX has surged nearly 90% since her buy, driven by strong earnings and renewed investor interest in animal health and diagnostics.
But IDEXX wasn’t an isolated call. Delaney’s 2025 portfolio shows a pattern of well-timed bets in sectors that overlap with her committee work, biotech, healthcare, and industrials.
Take STERIS (STE:US), her October buy. The company specializes in sterilization and surgical equipment and even works with NASA on spacecraft sterilization. That trade directly touches on her Science and Space Committee purview, a theme that’s becoming common across her filings.
Delaney has also made steady industrial and insurance bets that reflect a pragmatic streak:
ITT Inc (ITT:US), bought around $139 in March, is now up over 35%, fueled by U.S. infrastructure spending.
Markel Group (MKL:US), a Berkshire-style insurer she’s bought repeatedly between $1,790 and $1,969, trades near $2,060, a 5–15% gain on conviction buys.
Jones Lang LaSalle (JLL:US), acquired in the $240–270 range, has climbed past $300, riding the early stages of a commercial real estate rebound.
Her biotech bets extend beyond IDEXX too. Bio-Techne Corp (TECH:US) delivered a quick 10% win before she trimmed her position, showing she’s not afraid to take profits. On the other hand, Clean Harbors (CLH:US) was among the names she loaded off, she sold near $242 before the stock slipped to around $207, yet another display of immaculate timing.
And while her early-year focus was heavy on biotech and diagnostics, recent filings suggest diversification: new positions in Nasdaq (NDAQ:US), Brown & Brown (BRO:US), LabCorp (LH:US), and Tractor Supply (TSCO:US), each within the $1K–$50K range.
LabCorp, in particular, looks promising, up nearly 8% since her October buy, keeping her healthcare streak intact.
What stands out across her trades is consistency. Delaney isn’t chasing meme stocks or high-risk tech names; her buys are concentrated in regulated, committee-adjacent industries - healthcare, insurance, and infrastructure - sectors that quietly benefit from the very legislation her committees shape.
It’s not the most blatant example of political trading we’ve seen, but it’s certainly one of the most well-timed. From a near-perfect biotech call to solid industrial returns, Rep. April Delaney’s portfolio reflects a blend of precision, pattern, and perhaps a bit of privilege.
And that’s exactly why we track the politicians.
